Table 1.
P. falciparum infections and AS treatment outcomes in Aotus
| Parasite line | K13 580 residue | Aotus ID | Spleen status | Previous infection? | Prepatent period, d | AS dose, mg/kg/d × 3 | Initial P, % | Recrudescence information | WWARN t1/2 (ring-stage) | Joinpoint t1/2 (ring-stage) | AHL95 t1/2 (ring-stage) |
| GB4 | C | 86329 | Sp− | Yes, FVO | 7 | 4 | 1.63 | NO | 4.61 | 5.85 | 4.91 |
| GB4 | C | 86355 | Sp− | No | 10 | 4 | 0.74 | 25 DPT; CS | ND | 7.31 | 7.20 |
| GB4 | C | 86489 | Sp− | No (PINP) | 10 | 4 | 1.37 | 11 DPT | 17.36 | 7.03 | 7.85 |
| 4 | 2.45 | ND; “R1” | 9.27 | 7.20 | 5.76 | ||||||
| GB4 | C | 86574 | Sp− | Yes, FVO | 7 | 4 | 1.13 | NO | 6.79 | 4.57 | 4.39 |
| 61D3 | C | 86354 | Sp− | No | 17 | 4 | 2.68 | NO | 13.00 | 10.48 | 6.93 |
| 61D3 | C | 86484 | Sp− | No (PINP) | 3 | 2 | 3.78 | 11 DPT | 5.95 | 8.45 | 6.58 |
| 87E7 | Y | 86349 | Sp− | No | 15 | 4 | 3.05 | NO | 8.07 | 7.72 | 6.90 |
| 85G7 | Y | AI2045 | Sp− | Yes, Pv | 10 | 4 | 1.14 | 18 DPT; CS | 7.76 | 9.96 | 8.23 |
| 85G7 | Y | AI2049 | Sp− | Yes, Pv | 10 | 4 | 0.96 | 19 DPT; CS | 7.20 | 9.73 | 10.04 |
| 76H10 | Y | 86416 | Sp− | Yes, FVO | 5 | 4 | 1.31 | NO | 4.71 | 8.46 | 6.58 |
| 76H10 | Y | 86458 | Sp− | No (PINP) | 19 | 4 | 1.14 | NO | 5.91 | 9.66 | 7.40 |
| 76H10 | Y | 86527 | Sp− | No | 6 | 4 | 1.13 | 20 DPT; CS | 11.10 | 8.69 | 8.39 |
| 76H10 | Y | 86564 | Sp− | No | 6 | 2 | 0.96 | 35 DPT; CS | 10.98 | 7.75 | 8.12 |
| 76H10C580Rev | C | 86236 | Sp− | Yes, Pv | 24 | 4 | 2.03 | 23 DPT | 6.32 | 10.78 | 4.54 |
| 4 | 3.80 | 15 DPT; “R1” | 5.34 | 9.45 | 6.72 | ||||||
| 4 | 1.49 | 19 DPT; “R2” | 10.60 | 8.47 | 6.73 | ||||||
| 4 | 2.41 | 17 DPT; “R3” | 8.04 | 7.43 | 7.54 | ||||||
| 4 | 1.26 | 18 DPT; “R4” | ND | 7.08 | 7.30 | ||||||
| 4 | 2.59 | 21 DPT; “R5” | 4.71 | 7.44 | 7.17 | ||||||
| 4 | 1.36 | 23 DPT; “R6” | 9.41 | 10.40 | 8.49 | ||||||
| 4 | 1.22 | 29 DPT; “R7” | 11.69 | 5.57 | 7.17 | ||||||
| 4 | 1.84 | 26 DPT; “R8” | 6.83 | 7.56 | 6.23 | ||||||
| 4 | 1.03 | 40 DPT; “R9” | 8.84 | 8.31 | 8.65 | ||||||
| 4 | 0.96 | 37 DPT; “R10” | 11.89 | 8.05 | 7.46 | ||||||
| 4 | 2.05 | 56 DPT; “R11” | 6.70 | 7.92 | 5.76 | ||||||
| 4 | 1.03 | 33 DPT; “R12” | 10.42 | 10.87 | 12.82 | ||||||
| 4 | 0.90 | NO; “R13” | 6.16 | 9.70 | 8.81 | ||||||
| 76H10C580Rev | C | 86381 | Sp− | Yes, FVO | 6 | 4 | 2.05 | 22 DPT; CS | 4.90 | 7.19 | 6.05 |
| 76H10C580Rev | C | 86383 | Sp− | Yes, Pv | 26 | 4 | 1.26 | 25 DPT | 6.20 | 7.31 | 4.10 |
| 4 | 0.87 | 31 DPT; “R1” | 9.27 | 9.22 | 7.25 | ||||||
| 76H10C580Rev | C | 86404 | Sp− | No (PINP) | 42 | 4 | 1.45 | 18 DPT; CS | 6.45 | 11.54 | 6.32 |
| FVO | C | 86329 | Sp+ | No | 2 | 4 | 0.95 | 17 DPT | 7.95 | 4.16 | 4.95 |
| FVO | C | 86381 | Sp− | No | 2 | 4 | 0.99 | 10 DPT | 6.52 | 8.33 | 7.28 |
| FVO | C | 86416 | Sp− | No | 2 | 4 | 1.11 | 7 DPT | 12.97 | 6.55 | 6.89 |
| FVO | C | 86436 | Sp+ | No | 4 | 4 | 8.97 | 10 DPT | 5.17 | 6.86 | 5.89 |
| FVO | C | 86574 | Sp+ | No | 2 | 4 | 0.81 | 7 DPT | 5.99 | 3.87 | 5.29 |
CS, cleared to subpatent levels without antimalarial treatment; DPT, days posttreatment; NO, not observed by microscopic evaluation; ND, not determined; PINP, previously inoculated with Plasmodium but did not develop parasitemia; P, parasitemia; Pv, Plasmodium vivax; “R1”–“R13”, labeled recrudescences after treatments AS1–AS13 (Fig. 2 B and C).